The purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Eligible disease(s) / stage(s): Locoregionally advanced EBV positive NPC (T3-4, any N OR any T, N1-3. No M1) per AJCC v 8
Prior therapy: None for NPC permitted
Life expectancy: 3 months at least
Contraception requirements: Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control during treatment with toripalimab and for 4 months after the last dose.
Prior systemic anticancer treatment for NPC
Prior radiation to head and neck region or regions necessitating overlapping fields
Concurrent use of any anti- cancer treatment, standard, alternative or investigational.
History of allergic reactions to any agents in this study